12.92
+0.35(+2.78%)
Currency In USD
| Previous Close | 12.57 |
| Open | 12.57 |
| Day High | 13.05 |
| Day Low | 12.54 |
| 52-Week High | 13.08 |
| 52-Week Low | 8.73 |
| Volume | 8.6M |
| Average Volume | 5.92M |
| Market Cap | 8.82B |
| PE | -11.85 |
| EPS | -1.09 |
| Moving Average 50 Days | 11.59 |
| Moving Average 200 Days | 11.19 |
| Change | 0.35 |
If you invested $1000 in Roivant Sciences Ltd. (ROIV) since IPO date, it would be worth $1,242.31 as of September 08, 2025 at a share price of $12.92. Whereas If you bought $1000 worth of Roivant Sciences Ltd. (ROIV) shares 3 years ago, it would be worth $3,501.36 as of September 08, 2025 at a share price of $12.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
GlobeNewswire Inc.
Sep 03, 2025 5:01 PM GMT
First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response, resulting in normal thyroid function (T3 and T4 les
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
GlobeNewswire Inc.
Jul 28, 2025 8:05 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, August 11, 2025, to report its financial results fo
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
GlobeNewswire Inc.
Jun 09, 2025 8:05 PM GMT
BASEL, Switzerland and LONDON and NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced that they will host a live investor video conference at 1:00 PM ET on Tuesday, June 17 on brepocitinib, t